Price$136.95-5.13 (-3.61%)
02:00 PM07:45 PM
News · 26 weeks64-86%
2025-12-142026-06-07
Mix5390d
- Insider36(68%)
- Other11(21%)
- SEC Filings4(8%)
- Offering1(2%)
- Leadership1(2%)
Latest news
25 items- PRBelite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceSAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 pm ET. Webcast Link InstructionsWebcasts of the presentations can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events. The replays will be archived for 90 days f
- SECSEC Form 6-K filed by Belite Bio Inc6-K - BELITE BIO, INC (0001889109) (Filer)
- PRBelite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate UpdateInitiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected to be completed in the second quarter of 2026Commercialization preparation for STGD1 underway; hiring of all key commercial leadership positions completed Cash and cash equivalents, U.S. treasury bills and notes: $798.6 million as of March 31, 2026Conference call and webcast on Wednesday, May 20, 2026, at 4:30 p.m. ET SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing nov
- PRBelite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in SwitzerlandTinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease, having met the primary endpoint, reductions in lesion growth rate, in the pivotal, global Phase 3 DRAGON trial Company recently initiated a rolling submission of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA), which it expects to complete in 2Q 2026 Tinlarebant has previously been granted Breakthrough Therapy, Fast Track and Rare Pediatric Disease Designations in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and Pioneer Drug Designation in Japan for the treatment of Stargardt disease SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- Belite Bi
- PRBelite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), ("Belite Bio®" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give an oral presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) being held from May 21-23, 2026, in Nanjing, China. The presentation will cover the previously disclosed positive topline results from the Phase 3 DRAGON trial, which evaluated tinlarebant for the treatment of Stargardt disease type 1 (STGD1). In the
- PRBelite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial ResultsSAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), ("Belite Bio®" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Wednesday, May 20, 2026, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the first quarter ended March 31, 2026. Webcast InformationDate: Wednesday, May 20, 2026Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)Webcast Link: https://events.q4inc.com/attendee/135456520 Webcast Link InstructionsYou
- INSIDERChief Scientific Officer Mata Nathan L. sold $102,039 worth of American depositary share (666 units at $153.21) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Scientific Officer Mata Nathan L. sold $153,839 worth of American depositary share (1,000 units at $153.84) as part of a pre-agreed trading plan, decreasing direct ownership by 60% to 666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Scientific Officer Mata Nathan L. sold $155,502 worth of American depositary share (1,000 units at $155.50) as part of a pre-agreed trading plan, decreasing direct ownership by 38% to 1,666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Scientific Officer Mata Nathan L. sold $155,636 worth of American depositary share (1,000 units at $155.64) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 2,666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Scientific Officer Mata Nathan L. sold $155,778 worth of American depositary share (1,000 units at $155.78) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 3,666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Scientific Officer Mata Nathan L. sold $156,973 worth of American depositary share (1,000 units at $156.97) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 4,666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Scientific Officer Mata Nathan L. sold $155,817 worth of American depositary share (1,000 units at $155.82) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 5,666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Scientific Officer Mata Nathan L. sold $159,162 worth of American depositary share (1,000 units at $159.16) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 6,666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- PRDeutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online ViewingNEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held April 28th are now available for online viewing. VIEW PRESENTATIONS HERE The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section. April 28th Company Presentations Lotus Technology Inc. (NASDAQ:LOT)Viomi Technology Co., Ltd (NASDAQ:VIOT)Belite Bio, Inc (NASDAQ:BLTE)First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)HUTCHMED (China) Limited (AIM:
- INSIDERChief Scientific Officer Mata Nathan L. sold $162,641 worth of American depositary share (1,000 units at $162.64) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 7,666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Scientific Officer Mata Nathan L. sold $159,556 worth of American depositary share (1,000 units at $159.56) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 8,666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- PRBelite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation SummitSAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ:BLTE), ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give an oral presentation at the Retinal Therapeutics Innovation Summit being held on May 1, 2026, in Denver, Colorado. The presentation will cover the previously disclosed positive topline results from the Phase 3 DRAGON trial, which evaluated tinlarebant for the treatment of Stargardt disease type 1 (STGD1). In the study, tinlarebant demonstrated a clinically m
- INSIDERChief Scientific Officer Mata Nathan L. sold $166,284 worth of American depositary share (1,000 units at $166.28) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 9,666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Executive Officer Lin Yu-Hsin acquired 10,000 units of Ordinary Share, increasing direct ownership by 6% to 182,949 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Scholl Hendrik Peter4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Scientific Officer Mata Nathan L. sold $170,384 worth of American depositary share (1,000 units at $170.38) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 10,666 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- INSIDERChief Financial Officer Chuang Hao-Yuan acquired 10,000 units of Ordinary Share, increasing direct ownership by 5% to 205,264 units (SEC Form 4)4 - BELITE BIO, INC (0001889109) (Issuer)
- PRInternational companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on April 28, 2026NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference ("dbVIC") on Tuesday, April 28, 2026 featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the United States. Representatives from participating companies based in Australia, China, Hong Kong, Portugal, Netherlands, Cayman Islands and France, will respond to questions during formal presentations. The conference is targeted to all categories of investors and analysts interested in international companies. There is no fee for participants to log in, attend live presentations and/or ask qu
- PRBelite Bio to Participate in Four Upcoming Investor ConferencesSAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in four upcoming investor conferences. Details of the presentations are as follows: Deutsche Bank American Depositary Receipt Virtual Investor Conference (Virtual) April 28, 2026, at 9:00 am ET, corporate presentation BofA Securities 2026 Health Care Conference (Las Vegas, NV) May 13, 2026, at 3:40 pm PT, fireside chat H.C. Wainwright 4th Annual BioConnect Nasdaq Inves
BLTE FAQ
7 questionsWhat does Belite Bio Inc do?
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease...Where does BLTE stock trade?
Belite Bio Inc (BLTE) is listed on NASDAQ.What sector and industry is BLTE in?
Belite Bio Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Belite Bio Inc go public?
Belite Bio Inc (BLTE) completed its IPO in 2022.What are analysts saying about BLTE?
Belite Bio Inc has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-01-26. Recent price targets range from $2500.00 to $4300.00.What companies are similar to BLTE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BLTE side-by-side with any of them on Quantisnow.How can I track BLTE on Quantisnow?
Quantisnow aggregates Belite Bio Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLTE to receive live email and push alerts on every new disclosure.